NewLimit announced the close of a $435 million funding round on Friday, bringing the privately held longevity company's valuation to $3.1 billion, according to a report from the Wall Street Journal. The updated valuation is more than three times the firm's worth a year ago.
The startup, which counts Coinbase CEO Brian Armstrong among its co-founders, is focused on therapies to reverse cellular aging. It has not yet commercialized any products. NewLimit says it intends to begin human studies next year for its lead compound, which targets alcohol-related liver disease.
The financing arrives as investor interest in compounds designed to slow or reverse aging has intensified. NewLimit joins a cohort of longevity-focused companies backed by technology entrepreneurs and other private capital as the space attracts growing attention.
Funding and valuation
The $435 million infusion raises NewLimit's valuation to $3.1 billion, a mark that the report notes is more than triple the firm's valuation from twelve months earlier. The company completed the round on a Friday, closing the financing that produced the new valuation figure cited in the Wall Street Journal report.
Pipeline and development timeline
NewLimit does not have products on the market. Its stated near-term clinical plan is to initiate human testing next year for a drug candidate focused on alcohol-related liver disease. Beyond that timeline, the company has not announced commercial launches or marketed therapies.
Market context
The round comes amid broader momentum for aging-related drug research and development. The firm's fundraising places it alongside other longevity startups that have drawn financing from high-net-worth technology founders and private investors.
This article presents the financing, valuation, development status and near-term clinical plans as reported. Where details were limited in the reporting, those limitations are reflected rather than expanded upon.